MedDataX Logo

Effect of Brivaracetam in Photosensitive Epileptic Subjects

NCT ID: NCT00401648

Last Updated: 2009-12-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-09-30

Study Completion Date

2003-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

to assess the effect of brivaracetam on the photoparoxysmal EEG response in photosensitive epileptic subjects

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

POC photosensitive epileptic brivaracetam PPR AED

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Brivaracetam

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* epileptic subjects with generalized PPR

Exclusion Criteria

* more than 2 concomitant antiepileptic drugs
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

UCB Pharma

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philipp von Rosenstiel, MD.

Role: STUDY_DIRECTOR

UCB Pharma

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Marseille, , France

Site Status

Paris, , France

Site Status

Rouen, , France

Site Status

Strasbourg, , France

Site Status

Kork, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Protocol Number RPCE02D2304

Identifier Type: -

Identifier Source: secondary_id

N01069

Identifier Type: -

Identifier Source: org_study_id